Artificial intelligence (AI)-based drug developer Isomorphic Labs said it has raised $600 million in its first external funding round, with the proceeds expected to accelerate its research and ...

Goldman Sachs estimates that AI drug discovery and breakthroughs like gene editing will add 0.5% to 2.5% to the U.S. gross ...

AI, and cloud computing towards improving existing computational methods while exploring new algorithms to address a wide range of drug design challenges. “We look forward to helping expedite ...

Demis Hassabis, the co-founder and CEO of Google DeepMind, has made an audacious claim that artificial intelligence could ...

Its deal with the US-based AI-driven drug design and development company will see Cloud design novel small-molecule agents to GSK-specified targets. Ed Addison, CEO of Cloud Pharmaceuticals ...

Google DeepMind CEO Demis Hassabis believes we might be closer to that future than we think. In a recent appearance on CBS’ ...

The AI-first drug design and development company plans to utilize the investment to advance its AI drug design engine, enhance software capabilities, finance drug development programs, and ...

New center will use cutting-edge AI to accelerate the creation of life-saving medicines AI Small Molecule Drug Discovery Center Photo 1 Left to Right: Ethan Grimes, BS, and Paul Morgan, MD, conduct ...

We may make money when you click on links to our partners. Learn More. AI drug design and development company Isomorphic Labs announced on Monday that it raised $600 million in its first external ...

The funding will accelerate further development of Isomorphic’s AI drug design engine and support the company’s goal of bringing its discovered drugs to clinical trials. Isomorphic Labs was ...

Isomorphic Labs raised $600 million in its first external funding round to boost its artificial-intelligence drug design pipeline across multiple therapeutic areas.

The company is building what it describes as an AI drug design engine. The software reduces the amount of manual work involved in developing new medicines and thereby speeds up the process.